# Ceptur Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ceptur-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.cepturtx.com
- Total disclosed funding: $28M
- Latest round: Series A (Jan 18, 2022)
- Investors on record: 8

## About

Based in New Jersey, US, and founded in 2008, Ceptur Therapeutics, Inc. operates as a biotechnology company that develops genetic medicines for patients with unaddressed diseases based on U1 Adaptor technology. In January 2022 the company completed USD 75 million in Series A financing co-led by venBio Partners and Qiming Venture Partners USA. In 2021 the company licensed and expanded the foundational IP portfolio on U1 Adaptor technology and recruited industry leaders in oligonucleotide therapeutics. New members of Ceptur's Scientific Advisory Board include Dr. Thomas L. Andresen, CEO of T-Cypher Bio, Dr. Steven. F. Dowdy, professor of Cellular & Molecular Medicine at UCSD, and other doctors. 

Ceptur develops genetic medicines using its U1 Adaptor technology. The U1 adaptors are used to engage a ribonucleoprotein splicing factor which is used to promote gene silencing. This therapy can be used to tackle a wide range of diseases in oncology, the central nervous system, nephrology, and immunology. 

With the Series A funding from January 2022, Ceptur Therapeutics will build out its team and capabilities and advance novel therapeutics for patients with genetic diseases.

## Funding rounds

- Series A, Jan 18, 2022, $22M — Qiming Venture Partners, Bristol-Myers Squibb Company, VenBio, Perceptive Advisors, Boxer Capital, Janus Henderson Investors, LifeSci Partners, Affinity Asset Advisors
- Seed, Jul 29, 2020, $6.2M — Boxer Capital, LifeSci Partners, Affinity Asset Advisors

## Investors

- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Seed, Series A
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Seed, Series A
- Affinity Asset Advisors (https://capitalatlas.ai/funds/affinity-asset-advisors) — Seed, Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Bristol-Myers Squibb Company — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A
- Janus Henderson Investors — Series A